These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36527133)

  • 1. Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.
    Sgroi DC; Treuner K; Zhang Y; Piper T; Salunga R; Ahmed I; Doos L; Thornber S; Taylor KJ; Brachtel E; Pirrie S; Schnabel CA; Rea D; Bartlett JMS
    Breast Cancer Res; 2022 Dec; 24(1):90. PubMed ID: 36527133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
    Bartlett JMS; Sgroi DC; Treuner K; Zhang Y; Ahmed I; Piper T; Salunga R; Brachtel EF; Pirrie SJ; Schnabel CA; Rea DW
    Ann Oncol; 2019 Nov; 30(11):1776-1783. PubMed ID: 31504126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR
    Noordhoek I; Treuner K; Putter H; Zhang Y; Wong J; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; van de Velde CJH; Schnabel CA; Liefers GJ
    Clin Cancer Res; 2021 Jan; 27(1):311-319. PubMed ID: 33109739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer.
    O'Regan RM; Zhang Y; Fleming GF; Francis PA; Kammler R; Viale G; Dell'Orto P; Lang I; Bellet M; Bonnefoi HR; Tondini C; Villa F; Bernardo A; Ciruelos EM; Neven P; Karlsson P; Müller B; Jochum W; Zaman K; Martino S; Geyer CE; Jerzak KJ; Davidson NE; Coleman RE; Ingle JN; van Mackelenbergh MT; Loi S; Colleoni M; Schnabel CA; Treuner K; Regan MM
    JAMA Oncol; 2024 Oct; 10(10):1379-1389. PubMed ID: 39145953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study.
    Bartlett JMS; Sgroi DC; Treuner K; Zhang Y; Piper T; Salunga RC; Ahmed I; Doos L; Thornber S; Taylor KJ; Brachtel EF; Pirrie SJ; Schnabel CA; Rea DW
    Clin Cancer Res; 2022 May; 28(9):1871-1880. PubMed ID: 35144966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.
    Habel LA; Sakoda LC; Achacoso N; Ma XJ; Erlander MG; Sgroi DC; Fehrenbacher L; Greenberg D; Quesenberry CP
    Breast Cancer Res; 2013 Mar; 15(2):R24. PubMed ID: 23497539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), Ki67 changes and their clinical significance between primary breast cancer and metastatic tumors.
    Qi G; Zhang X; Gai X; Yan X
    PeerJ; 2024; 12():e17377. PubMed ID: 38766488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.
    Sgroi DC; Carney E; Zarrella E; Steffel L; Binns SN; Finkelstein DM; Szymonifka J; Bhan AK; Shepherd LE; Zhang Y; Schnabel CA; Erlander MG; Ingle JN; Porter P; Muss HB; Pritchard KI; Tu D; Rimm DL; Goss PE
    J Natl Cancer Inst; 2013 Jul; 105(14):1036-42. PubMed ID: 23812955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.
    Ma XJ; Hilsenbeck SG; Wang W; Ding L; Sgroi DC; Bender RA; Osborne CK; Allred DC; Erlander MG
    J Clin Oncol; 2006 Oct; 24(28):4611-9. PubMed ID: 17008703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
    Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
    Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long-term follow-up.
    Lashen AG; Toss MS; Mongan NP; Green AR; Rakha EA
    Cancer; 2023 Apr; 129(8):1183-1194. PubMed ID: 36653923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
    Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
    Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
    Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
    Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study.
    Shokouh TZ; Ezatollah A; Barand P
    Medicine (Baltimore); 2015 Aug; 94(32):e1359. PubMed ID: 26266392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer.
    Wang Z; Dahiya S; Provencher H; Muir B; Carney E; Coser K; Shioda T; Ma XJ; Sgroi DC
    Clin Cancer Res; 2007 Nov; 13(21):6327-34. PubMed ID: 17975144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
    Khande TA; Joshi AR; Khandeparkar SGS; Kulkarni MM; Gogate BP; Kakade AR; Sahu PD; Khillare CD
    Indian J Cancer; 2020; 57(2):190-197. PubMed ID: 32445323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015-2018.
    Stevanovic L; Choschzick M; Moskovszky L; Varga Z
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):2983-2994. PubMed ID: 31628534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
    Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
    Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2- breast cancer: a retrospective cohort study.
    Xie Y; Li X; Wu Y; Cui W; Liu Y
    World J Surg Oncol; 2022 Oct; 20(1):338. PubMed ID: 36224558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.